Clinical

Dataset Information

0

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation


ABSTRACT: This is a multicenter, open-label, Phase 1B/2 study to evaluate the safety and assess the preliminary anti-tumor activity of binimetinib administered in combination with nivolumab or nivolumab + ipilimumab in adult patients with advanced metastatic colorectal cancer (mCRC) with microsatellite stable (MSS) disease and presence of a RAS mutation that have received at least one prior line of therapy and no more than 2 prior lines of therapy. The study contains a Phase 1b period to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and schedule of binimetinib followed by a randomized Phase 2 period to assess the efficacy of the combinations.

DISEASE(S): Metastatic Colorectal Cancer,Microsatellite-stable (mss) Metastatic Colorectal Cancer With Ras Mutation,Ras-mutant Colorectal Cancer,Colorectal Neoplasms,Mss,Cancer

PROVIDER: 2253431 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-10-24 | GSE268364 | GEO
2021-06-09 | GSE159237 | GEO
2024-01-01 | GSE202361 | GEO
2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress
2024-01-09 | GSE234136 | GEO
| 2285884 | ecrin-mdr-crc
| 2353637 | ecrin-mdr-crc
2018-05-22 | GSE114716 | GEO
| 2312809 | ecrin-mdr-crc
| EGAS00001005501 | EGA